Jaguar Health (NASDAQ:JAGX) | Finanzwire

Basculer en Français

8296	Companies
114905	Keywords
55332	Articles
62461	Press releases

Home
Companies
Jaguar Health

BRIEF

published on 07/18/2024 at 16:35, 4 months 2 days ago

Jaguar Health to Report Phase 3 OnTarget Trial Results for Crofelemer on July 23rd

Crofelemer Webcast Jaguar Health OnTarget Trial Cancer Supportive Care
PRESS RELEASE

published on 07/18/2024 at 16:30, 4 months 2 days ago

Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning
Jaguar Health announces webcast for cancer supportive care updates including OnTarget trial results. Make Cancer Less Shitty program expands with MCLS Ambassadors

Webcast Jaguar Health OnTarget Trial Cancer Supportive Care Make Cancer Less Shitty
BRIEF

published on 07/08/2024 at 16:35, 4 months 12 days ago

Jaguar Health Strengthens IP Protection with New European and Australian Patents

Crofelemer Jaguar Health Australian Patent European Patent SBS And CDDs
PRESS RELEASE

published on 07/08/2024 at 16:30, 4 months 12 days ago

Issuance of New European & Australian Patents Bolster IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs)
New patents issued for core rare disease target indications for crofelemer. Jaguar Health announces new patents from European Patent Office and IP Australia for Napo Pharmaceuticals' crofelemer. Expected results in 2024 and 2025

Napo Pharmaceuticals Crofelemer Jaguar Health Patents Rare Disease

Accesswire

Published on 11/21/2024 at 13:30, 26 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 26 minutes ago

Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 56 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 56 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 56 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 41 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 21 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 41 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 49 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 56 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 58 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 36 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 11 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 11 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE